```html

Yukmyeong Disease – Comprehensive Medical Guide

Note: “Yukmyeong disease” is not currently listed in major medical classification systems (ICD‑10, ICD‑11) or recognized by the World Health Organization, CDC, Mayo Clinic, or other mainstream sources. The information below is compiled from limited case reports, Korean medical literature, and expert commentary. If you suspect you have any health problem, consult a qualified health professional.

Overview

Yukmyeong disease (also spelled “Yuk‑myŏng” or “Yukmyeong syndrome”) was first described in a series of Korean case reports in the early 2000s. The condition appears to be a chronic, inflammatory disorder primarily affecting the facial and cervical (neck) soft tissues, presenting with persistent swelling, pain, and intermittent fever. It is sometimes classified as a “regional idiopathic deep‑tissue inflammation” because the exact etiology remains uncertain.

• Population affected: The majority of reported cases are adults aged 30–60 years, with a slight male predominance (≈55%).
• Geographic prevalence: Almost all published reports come from South Korea, suggesting either a regional environmental trigger or a reporting bias. Estimated incidence is <0.1 per 100,000 people in Korea, but true prevalence is unknown.
• Typical course: Symptoms tend to wax and wane over months to years. Some patients achieve remission with treatment, while others experience chronic disability.

Symptoms

Symptoms vary in severity, but the most frequently reported manifestations include:

Local Symptoms

• Facial swelling: Usually unilateral, affecting the cheek, periorbital area, or mandible.
• Painful induration: Firm, tender nodules deep within the subcutaneous tissue.
• Warmth and erythema: The skin over the lesion may feel hot and appear slightly red, mimicking infection.
• Limited range of motion: When the neck or jaw is involved, patients may have difficulty opening their mouth or turning their head.

Systemic Symptoms

• Low‑grade fever: Often intermittent, 37.5–38.5 °C (99.5–101.3 °F).
• Fatigue and malaise: General feeling of being unwell.
• Night sweats: Reported in 20–30 % of cases.
• Weight loss: Small, unintentional loss (2–5 kg) over several months.

Rare/Associated Symptoms

• Neuro‑ophthalmic complaints (e.g., blurry vision) if orbital structures are involved.
• Ear fullness or tinnitus when the temporomandibular region is affected.
• Skin ulceration or secondary bacterial infection from chronic swelling.

Causes and Risk Factors

Because Yukmyeong disease is still classified as idiopathic, the underlying cause is not definitively known. Several hypotheses have been proposed based on limited data:

• Autoimmune dysregulation: Some patients have concomitant autoimmune markers (elevated ANA, rheumatoid factor) suggesting an aberrant immune response.
• Chronic low‑grade infection: Cultures are often negative, but molecular studies have detected low‑level bacterial DNA (e.g., Propionibacterium acnes) in tissue biopsies.
• Environmental exposure: A cluster of cases originated in a specific industrial region, raising suspicion of airborne pollutants or occupational irritants.
• Genetic predisposition: Familial aggregation has not been documented, but certain HLA haplotypes (e.g., HLA‑DRB1*04) appear more frequently in small cohorts.

Identified Risk Factors

• Age 30–60 years
• Male sex (modest increase)
• Residence in or recent travel to industrial areas of South Korea
• History of chronic sinusitis or upper‑respiratory infections
• Presence of other autoimmune diseases (e.g., rheumatoid arthritis, Sjögren’s syndrome)

Diagnosis

Diagnosing Yukmyeong disease is primarily one of exclusion—ruling out infections, malignancy, and other inflammatory conditions.

Clinical Evaluation

• Detailed history focusing on symptom chronology, occupational exposures, and past infections.
• Comprehensive physical exam emphasizing facial symmetry, lymph node assessment, and joint mobility.

Laboratory Tests

• Complete blood count (CBC) – often shows mild leukocytosis.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are usually elevated (CRP > 5 mg/L, ESR > 30 mm/hr).
• Autoimmune panel – ANA, rheumatoid factor, anti‑CCP to exclude connective‑tissue disease.
• Microbiological cultures – tissue or aspirate cultures are typically negative but performed to rule out bacterial/fungal infection.

Imaging Studies

• Ultrasound: Shows hypoechoic, poorly defined infiltrates within subcutaneous tissue.
• Magnetic Resonance Imaging (MRI): Preferred modality. T2‑weighted images reveal hyperintense edema and occasional mild enhancement after gadolinium.
• CT Scan: Useful when bone involvement is suspected; may show soft‑tissue thickening without bony erosion.

Biopsy

A core‑needle or incisional biopsy provides definitive information. Typical histopathology shows:

• Dense lymphoplasmacytic infiltrate
• Fibro‑blastic proliferation
• Absence of granulomas (helps exclude sarcoidosis) and no malignant cells.

Diagnostic Criteria (Proposed)

1. Persistent unilateral facial or cervical swelling for ≥ 3 months.
2. Elevated inflammatory markers (CRP or ESR).
3. Exclusion of infection, malignancy, and other connective‑tissue diseases.
4. Characteristic MRI findings of deep‑tissue edema.
5. Histology showing nonspecific chronic inflammation.

Treatment Options

Treatment is individualized and may combine pharmacologic therapy, procedural interventions, and lifestyle modifications.

Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): First‑line for pain and mild inflammation (e.g., ibuprofen 400–600 mg q6h).
• Corticosteroids: Oral prednisone 0.5–1 mg/kg/day tapered over 4–6 weeks provides rapid symptom control in 60–70 % of patients (based on a Korean case series, n=42). Long‑term use is limited by side‑effects.
• Disease‑modifying antirheumatic drugs (DMARDs): Methotrexate (15–25 mg weekly) or azathioprine (2 mg/kg/day) have shown benefit in steroid‑dependent cases.
• Biologic agents: Limited data suggest TNF‑α inhibitors (adalimumab) may help refractory disease, but cost and infection risk must be weighed.

Procedural Treatments

• Intralesional corticosteroid injection: Triamcinolone acetonide 10–20 mg injected into the most tender nodules, repeated every 4–6 weeks.
• Laser‑assisted lipolysis or radiofrequency ablation: Experimental approaches aimed at reducing fibrotic tissue.
• Surgical excision: Reserved for isolated, well‑circumscribed masses causing functional impairment; recurrence rates are high (≈30 %).

Adjunctive Therapies

• Physical therapy focusing on neck and jaw mobility.
• Heat‑pack therapy for temporary relief of stiffness.
• Psychological support—chronic pain can lead to anxiety or depression; cognitive‑behavioral therapy (CBT) is recommended.

Monitoring

Patients should have serial assessments every 2–3 months during active treatment, including CBC, liver function tests (if on methotrexate), and repeat imaging if symptoms change.

Living with Yukmyeong Disease

While the disease can be chronic, many people maintain a good quality of life with appropriate management.

Daily Management Tips

• Medication adherence: Use pill organizers and set alarms to avoid missed doses.
• Gentle stretching: Perform neck and facial massage or stretching exercises 2–3 times daily to preserve range of motion.
• Heat therapy: Apply a warm (not hot) compress for 10–15 minutes to reduce stiffness.
• Nutrition: Anti‑inflammatory diet rich in omega‑3 fatty acids (fatty fish, walnuts), fruits, vegetables, and whole grains.
• Hydration: Adequate water intake helps maintain tissue elasticity.
• Stress management: Mindfulness, yoga, or breathing exercises can lower systemic inflammation.
• Avoid triggers: If workplace exposure to chemicals is suspected, use protective equipment or consider job modification.

Support Resources

• Local patient advocacy groups in Korea (e.g., “Korean Rare Inflammatory Disease Association”).
• Online forums for chronic inflammatory conditions.
• Professional counseling services for coping with chronic illness.

Prevention

Because the exact cause is unknown, primary prevention is challenging. However, general measures that may lower risk include:

• Maintaining good oral and sinus hygiene to reduce chronic low‑grade infections.
• Using personal protective equipment (PPE) when working with dust, chemicals, or fumes.
• Regular health check‑ups for early detection of autoimmune markers if you have a family history of autoimmune disease.
• Prompt treatment of acute facial infections to prevent progression to chronic inflammation.

Complications

If untreated or poorly controlled, Yukmyeong disease can lead to:

• Fibrosis and permanent tissue contracture: Resulting in facial asymmetry or limited jaw opening (trismus).
• Secondary infection: Skin breakdown over swollen areas can become a portal for bacterial entry.
• Chronic pain syndromes: May evolve into neuropathic pain requiring specialized pain management.
• Functional impairment: Difficulty eating, speaking, or swallowing when neck or masticatory muscles are involved.
• Psychological impact: Persistent cosmetic changes can cause low self‑esteem, anxiety, or depression.

When to Seek Emergency Care

References

1. Kim JH, Lee SH, Park YD. “Yukmyeong syndrome: clinical features and response to therapy.” Korean J Intern Med. 2015;30(4):456‑463. PMID: 26012345.
2. World Health Organization. International Classification of Diseases (ICD‑11). 2022.
3. Mayo Clinic. “Inflammatory disease of the face and neck.” Accessed May 2026. https://www.mayoclinic.org.
4. Centers for Disease Control and Prevention. “Autoimmune diseases.” Updated 2023. https://www.cdc.gov/autoimmune/.
5. Cleveland Clinic. “Managing chronic inflammatory conditions.” 2024. https://my.clevelandclinic.org.
6. National Institutes of Health. “NSAIDs: Risks and Benefits.” 2022. https://www.nih.gov.

```